Synovus Financial Corp Myovant Sciences Ltd. Transaction History

Synovus Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$11.6 - $20.44 $59,334 - $104,550	-5,115 Reduced 3.14%	158,017 $2.84 Million
Q2 2022 Aug 10, 2022	BUY	$7.78 - $14.69 $61,897 - $116,873	7,956 Added 5.13%	163,132 $2.03 Million
Q1 2022 May 12, 2022	BUY	$11.38 - $16.4 $703,522 - $1.01 Million	61,821 Added 66.22%	155,176 $2.07 Million
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $99,010 - $165,156	6,919 Added 8.0%	93,355 $1.45 Million
Q3 2021 Nov 08, 2021	SELL	$18.94 - $26.99 $45,152 - $64,344	-2,384 Reduced 2.68%	86,436 $1.94 Million
Q2 2021 Aug 11, 2021	BUY	$17.07 - $24.56 $188,282 - $270,896	11,030 Added 14.18%	88,820 $2.02 Million
Q1 2021 May 11, 2021	BUY	$20.46 - $25.18 $276,373 - $340,131	13,508 Added 21.01%	77,790 $1.59 Million
Q4 2020 Feb 11, 2021	BUY	$13.8 - $27.62 $68,448 - $136,995	4,960 Added 8.36%	64,282 $1.78 Million
Q3 2020 Nov 09, 2020	BUY	$14.05 - $22.6 $13,431 - $21,605	956 Added 1.64%	59,322 $836,000
Q2 2020 Aug 10, 2020	BUY	$7.34 - $20.84 $428,406 - $1.22 Million	58,366 New	58,366 $1.2 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Synovus Financial Corp with notifications on news.